Bioasis is happy to announce we have signed an agreement with a leading pharmaceutical company for pre-clinical research using the xB3 platform technology, Under the terms of the Material Transfer Agreement, Bioasis will receive $500,000. To learn more, please visit: https://www.bioasis.us/bioasis-announces-agreement-with-leading-pharmaceutical-company-for-pre-clinical-research-using-the-xb3-platform-technology/